Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45. https://doi.org/10.1002/art.10697

Article  PubMed  CAS  Google Scholar 

Cohen SB, Pope J, Haraoui B, Irazoque-Palazuelos F, Korkosz M, Diehl A, Rivas JL, Lukic T, Liu S, Stockert L, Iikuni N, Keystone EC (2019) Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatol 1:e23-e34. https://doi.org/10.1016/S2665-9913(19)30005-0 Erratum in: Lancet Rheumatol 1:e205. https://doi.org/10.1016/S2665-9913(19)30095-5

van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S (2006) TEMPO study investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–1074. https://doi.org/10.1002/art.21655

Article  PubMed  CAS  Google Scholar 

Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B et al (2013) Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 40:1487–1497. https://doi.org/10.3899/jrheum.120964

Article  PubMed  CAS  Google Scholar 

Curtis JR, Emery P, Karis E, Haraoui B, Bykerk V, Yen PK, Kricorian G, Chung JB (2021) Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis patients in Sustained Remission. Arthritis Rheumatol 73:759–768. https://doi.org/10.1002/art.41589

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, Kempis JV (2019) Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau Cohorts. J Clin Med 8:1548. https://doi.org/10.3390/jcm8101548

Article  PubMed  PubMed Central  CAS  Google Scholar 

Retuerto M, Trujillo E, Valero C, Fernandez-Espartero C, Soleto C, Garcia-Valle A, Aurrecoechea E, Garijo M, Lopez A, Loricera J, Pablos J (2021) Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: an observational study. Clin Exp Rheumatol 39:453–455. https://doi.org/10.55563/clinexprheumatol/cbanza

Article  PubMed  Google Scholar 

Ebina K, Hashimoto M, Yamamoto W et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. Arthritis Res Ther 21:114. https://doi.org/10.1186/s13075-019-1880-4

Article  PubMed  PubMed Central  Google Scholar 

Strand V, Miller P, Williams SA et al (2017) Discontinuation of Biologic Therapy in Rheumatoid Arthritis: analysis from the Corrona RA Registry. Rheumatol Ther 4:489–502. https://doi.org/10.1007/s40744-017-0078-y

Article  PubMed  PubMed Central  Google Scholar 

de Camargo MC, Barros BCA, Fulone I, Silva MT, Silveira MSDN, de Camargo IA, Barberato-Filho S, Del Fiol FS, Lopes LC (2019) Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving Long-Term Biological agents in a real-life setting. Front Pharmacol 10:965. https://doi.org/10.3389/fphar.2019.00965

Article  PubMed  PubMed Central  CAS  Google Scholar 

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794. https://doi.org/10.1002/14651858.CD008794.pub2

Article  PubMed  PubMed Central  Google Scholar 

Wolfe F (1995) The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 9:619–6 32. https://doi.org/10.1016/S0950-3579(05)80305-X

Bąk-Sosnowska M, Gruszczyńska M, Wyszomirska J, Daniel-Sielańczyk A (2022) The influence of selected psychological factors on Medication Adherence in patients with chronic diseases. Healthc (Basel) 10:426. https://doi.org/10.3390/healthcare10030426

Article  Google Scholar 

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A (2009) Swiss clinical Quality Management Physicians comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560–568. https://doi.org/10.1002/art.24463

Article  PubMed  Google Scholar 

Paroli M, Becciolini A, Bravi E, Andracco R, Nucera V, Parisi S, Ometto F, Lumetti F, Farina A, Del Medico P et al (2023) Long-term Retention Rate of Tofacitinib in Rheumatoid Arthritis: an Italian Multicenter Retrospective Cohort Study. Medicina 59:1480. https://doi.org/10.3390/medicina59081480

Article  PubMed  PubMed Central  Google Scholar 

Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846. https://doi.org/10.1111/j.1749-6632.200904621.x

Article  PubMed  CAS  Google Scholar 

Narongroeknawin P, Chevaisrakul P, Kasitanon N, Kitumnuaypong T, Mahakkanukrauh A, Siripaitoon B (2016) Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: analysis from the Thai Rheumatic Disease prior authorization registry. Int J Rheum Dis 21:170–178. https://doi.org/10.1111/1756-185x.12937

Article  PubMed  Google Scholar 

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T (2011) Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21:122–133. https://doi.org/10.1007/s10165-010-0366-7

Article  PubMed  CAS  Google Scholar 

Valero M, Sánchez-Piedra C, Freire M, Colazo M, Busquets N, Meriño-Ibarra E, Rodríguez-Lozano C, Manrique S, Campos C, Sánchez-Alonso F, Castrejón I (2023) Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry. Arthritis Res Ther 25:86. https://doi.org/10.1186/s13075-023-03045-3. Erratum in: Arthritis Res Ther 25:210. https://doi.org/10.1186/s13075-023-03194-5

Vander Cruyssen B, Van Looy S, Wyns B et al (2006) Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8:R112. https://doi.org/10.1186/ar2001

Article  PubMed  Google Scholar 

Emery P (2012) Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 51:22–30. https://doi.org/10.1093/rheumatology/kes115

Article  CAS  Google Scholar 

Du Pan SM, Scherer A, Gabay C et al (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71:997–999. https://doi.org/10.1136/annrheumdis-2011-200882

Article  PubMed  CAS  Google Scholar 

Tonin F, Steimbach L, Leonart L, Ferreira V, Borba H, Piazza T (2018) Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. Eur J Clin Pharmacol 74:1513–1521. https://doi.org/10.1007/s00228-018-2524-3

Article  PubMed  Google Scholar 

Curtis J, Patkar N, Xie A, Martin C, Allisson J, Saag M (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56:1125–1133. https://doi.org/10.1002/art.22504

Article  PubMed  CAS  Google Scholar 

Maini R, Breedveld F, Kalden J, Smolen J, Davis D, Macfarlane J et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563. https://doi.org/10.1002/1529-0131

Article  PubMed  CAS  Google Scholar 

van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558–567. https://doi.org/10.3899/jrheum.090856

Article  PubMed  CAS  Google Scholar 

Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) Suppl 6:vi5-9. https://doi.org/10.1093/rheumatology/kes279

van Gestel AM, Prevoo ML, van ’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League against Rheumatism criteria. Arthritis Rheum 39:34–40. https://doi.org/10.1002/art.1780390105

Article  PubMed  Google Scholar 

Barsky AJ, Peekna HM, Borus JF (2001) Somatic symptom reporting in women and men. J Gen Intern Med 16:266–275. https://doi.org/10.1046/j.1525-1497.2001.016004266.x

Article  PubMed  PubMed Central  CAS